You are here

Article Text

Article menu
Download PDFPDF
Case report
Fingolimod-associated central serous chorioretinopathy in a young girl
  1. Gajanan Chavhan Pratima,
  2. Doris Benita,
  3. Sandip Sarkar and
  4. Amit Kumar Deb
  1. Ophthalmology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Tamil Nadu, India
  1. Correspondence to Dr Amit Kumar Deb; amitjipmer{at}yahoo.co.in

Abstract

Fingolimod is a sphingosine-1-phosphate analogue used for the treatment of multiple sclerosis. We, hereby, report a rare case of fingolimod-associated central serous chorioretinopathy (CSCR) in a 21-year-old woman who presented with blurring of vision in the right eye 3 weeks after initiation of oral fingolimod. On examination, best-corrected visual acuity was 20/20 in both the eyes. Fundus examination revealed shallow, serous macular neurosensory detachment in the right eye, and it was confirmed with spectral domain optical coherence tomography. Left eye fundus was normal. Fluorescein angiography showed focal retinal pigment epithelium leak inferior to the fovea. A diagnosis of fingolimod-associated CSCR was made. Oral fingolimod was discontinued. Subsequent follow-up visits showed partial resolution of CSCR at 2 weeks and at 1 month and complete resolution of the subretinal fluid at 2 months. CSCR is, therefore, a rare adverse effect of oral fingolimod treatment. Baseline eye examination and subsequent follow-up at regular intervals are recommended for patients on fingolimod.

  • retina
  • macula

https://doi.org/10.1136/bcr-2021-243207

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors GCP reviewed the literature, prepared the manuscript. DB defined the intellectual content, analysed laboratory data, edited and reviewed the manuscript. SS provided the clinical details, managed the patient, edited and reviewed the manuscript. AKD provided the clinical details, managed the patient and edited and reviewed the manuscript. AKD as the guarantor accept full responsibility for the work, and had access to data, and controlled the decision to publish. The authors fully acknowledge the contribution of the patient to the research.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.